Great to be part of the conversation at MassBio’s State of Possible, where our CEO Andy Orth joined the Biotech CEOs on the Frontlines panel.
Andy shared our work philosophy, WFC (Work from City), & that for us, being together fuels creativity, deepens connection & accelerates scientific discovery.
Exciting week at Keystone Symposia! We shared new science from our differentiated RNAi platform, from peptide-enabled siRNA delivery to the CNS & eye, to cityRNAs as novel RNAi agents expanding RNA-based precision medicine.
On #IDWGS, we’re proud to recognize the women at City whose curiosity, expertise, and dedication help drive our science forward. We asked a few Citizens what it means to be a woman in this field, and their perspectives speak for themselves below.
City Therapeutics is #hiring across discovery, nonclinical, and clinical development. If you bring courage to tackle complex science, innovation to push boundaries, and the tempo to build with purpose, plus a collaborative “yes” mindset. Apply: www.citytx.com/home#culture
Proud moment for City: We’ve been named to BioSpace’s NextGen Class of 2026, recognizing top up-and-coming #lifescience companies in North America. We’re grateful for the recognition and proud of our team pushing innovative #RNAi therapeutics. www.biospace.com/nextgen
Festive moments at City this week, from a Yankee Swap to celebrating our NEVY Award win in City tees, plus spotting one all the way in Australia. We also gave back with @lifesciencecares.bsky.social and Hyde Square Task Force. We’re growing and hiring: www.citytx.com/home#culture
Congrats to City founder @jmaraganore.bsky.social on receiving the Lifetime Achievement Award by @BosBizJournal’s Innovators in Healthcare 2026! His commitment to translating innovation into patient impact is foundational to our efforts in RNAi therapeutics. www.bizjournals.com/boston/news/...
We’re excited to share that City Therapeutics won Emerging Company of the Year at New England VC’s 13th Annual #NEVYs25!
It’s a meaningful moment for our team as we continue advancing RNAi therapeutics with purpose, care, and recognized momentum.
Excited to announce the submission of our CTA to the @mhragovuk.bsky.social to initiate a Phase 1 study of CITY-FXI, an investigational RNAi therapeutic targeting Factor XI w/ the potential to safely & effectively prevent blood clots without increasing bleeding risk. www.citytx.com/news/city-th...
Honored to be named by LinkedIn as a Top 10 #LinkedInTopStartups of Boston in 2025! In the heart of Kendall Square, we’re building a place where careers & cutting-edge RNAi science can thrive. www.linkedin.com/pulse/linked...
One year strong, from growing our team to building partnerships, our focus is unwavering to reshape the future of RNAi medicines. Here's to what's next!
Check out City's Executive Chair, @jmaraganore.bsky.social presenting at Fierce Biotech Week 2025 this week, where he'll offer insights from his past and reflect on the evolving landscape of RNAi! www.fiercebiotechweek.com/event/fierce...
Exciting news from City! We’ve partnered with Biogen to develop select novel RNAi-based therapies leveraging our next-generation RNAi engineering technologies. Learn more: www.globenewswire.com/news-release...
Excited to welcome Baisong Mei, M.D., Ph.D., as CMO, Anna O’Driscoll as CHRO, and Sara Nochur, Ph.D., as an independent board member! Their expertise in life sciences will help drive our next phase of growth. Learn more below and at: www.businesswire.com/news/home/20...
